ZyversaREV_cmyk.jpg
ZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100’s Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its Complications
February 28, 2024 07:57 ET | ZyVersa Therapeutics
In obesity, inflammasome activation in fat tissue triggers cell death and release of inflammatory cytokines & ASC Specks, spreading damaging inflammation.
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic Option
February 22, 2024 07:47 ET | ZyVersa Therapeutics
Activation of multiple inflammasome pathways and extracellular ASC specks contribute to development and progression of common neurological diseases.
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics Highlights Review Article Substantiating That Inflammasome Activation Is Pathogenic in Multiple Neurological Diseases
February 14, 2024 07:53 ET | ZyVersa Therapeutics
Inflammation resulting from activation of more than one type inflammasome and ASC specks contribute to development and progression of neurological disease
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics Announces Peer-Reviewed Article Supporting the Therapeutic Potential of Targeting ASC Specks During Progression of Alzheimer’s Disease
January 24, 2024 07:57 ET | ZyVersa Therapeutics
Activation of the inflammasome/ASC speck pathway has a vital role in synaptic degeneration in Alzheimer’s Disease (AD).
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics Highlights Peer-Reviewed Article Linking Inflammasome Activation to Triple-Negative Breast Cancer Brain Metastasis
January 17, 2024 07:52 ET | ZyVersa Therapeutics
NLRP3 Inflammasome Activation Is Linked to Brain Metastasis in Patients with Triple-Negative Breast Cancer.
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics Announces Publication Demonstrating That Plasma Levels of NLRP3 Inflammasomes Correlate with Progression of Diabetic Kidney Disease in Patients with Type 2 Diabetes
December 07, 2023 11:20 ET | ZyVersa Therapeutics
Plasma NLRP3 inflammasomes are significantly elevated in early-stage diabetic kidney disease, and levels progressively increase as kidney function worsens.
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics Announces Article in Peer-Reviewed Journal, Ecotoxicology and Environmental Safety, Linking Air Pollution with Development and Progression of Chronic Kidney Disease That Can Be Attenuated by Inhibiting Inflammasome NLRP3 Activation
November 06, 2023 07:05 ET | ZyVersa Therapeutics
Air pollution linked with development and progression of chronic kidney disease that can be attenuated by inhibiting inflammasome NLRP3 activation.
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics Announces Publication in Molecular Neurobiology Reinforcing Data Demonstrating That Inflammasome ASC Inhibitor IC 100 Attenuates the Inflammatory Response Causing Neuronal Damage in Multiple Sclerosis Model, Potentially Providing Neuroprotection
November 01, 2023 08:07 ET | ZyVersa Therapeutics
NLRP3 Inflammasome Inhibition Alleviates Neurological Impairment in the Brain of MS Mouse Model, Reinforcing Published Data for IC 100 in MS Mouse Model.